Updates are available Correction dated 2019-04-23
Click to view Correction: https://doi.org/10.1007/s10157-019-01728-3
-
Authors
Fujisawa, Madoka
Kato, Hideki
Yoshida, Yoko
Usui, Tomoko
Takata, Munenori
Fujimoto, Mika
Wada, Hideo
Uchida, Yumiko
Kokame, Koichi
Matsumoto, Masanori
Fujimura, Yoshihiro
Miyata, Toshiyuki
Nangaku, Masaomi
-
Funding
Funding for this research was provided by:
The Ministry of Health, Labour, and Welfare of Japan
The Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (15K09246, 16K09834)
The Japanese Association for Complement Research
The Takeda Scientific Foundation
The Practical Research Project for Rare/Intractable Diseases from Japan Agency for Medical Research and Development, AMED (17ek0109254h0001)
- License Information
-
More Information
Article History
Received: 1 November 2017
Accepted: 22 February 2018
First Online: 6 March 2018
Change Date: 23 April 2019
Change Type: Correction
Change Date: 23 April 2019
Change Type: Correction
Change Details: The original article can be found online
Change Details: The original article can be found online
Compliance with ethical standards
:
: Yoshihiro Fujimura is a recipient of patent royalty for ADAMTS13 activity-ELISA kits from Alfressa, Honoraria: Hideki Kato and Masaomi Nangaku from Alexion Pharma, Hideo Wada from IL Japan and Alexion Pharma, and Masanori Matsumoto from Asahi Kasei Pharma and Alexion Pharma, Research funding: Masanori Matsumoto from Bayer Yakuhin, Chugai Pharmaceutical, and Asahi Kasei Pharma, Subsidies or Donations: Masaomi Nangaku from Alexion Pharma.
: Ethical approval: all procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee at which the studies were conducted (IRB approval number G10029) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.
